Is NOVAVAX INC (NVAX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 15.3% / 30% | 45.2% / 30% | 6.5% / 30% | 7.65% / 5% | ✗ NOT HALAL |
| DJIM | 15.3% / 33% | 45.2% / 33% | 6.5% / 33% | 7.65% / 5% | ✗ NOT HALAL |
| MSCI | 21.1% / 33% | 62.5% / 33% | 9.0% / 33% | 7.65% / 5% | ✗ NOT HALAL |
| S&P | 15.3% / 33% | 45.2% / 33% | 6.5% / 33% | 7.65% / 5% | ✗ NOT HALAL |
| FTSE | 21.1% / 33% | 62.5% / 33% | 9.0% / 50% | 7.65% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 63.5% | |
| Operating Margin | 14.2% | |
| Net Margin | 39.2% | |
| Return on Assets (ROA) | 25.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$245M |
| Free Cash Flow | -$251M |
| Total Debt | $249M |
| Current Ratio | 2.1 |
| Total Assets | $1.2B |
Price & Trading
| Last Close | $8.95 |
| 50-Day MA | $9.36 |
| 200-Day MA | $8.02 |
| Avg Volume | 5.1M |
| Beta | 2.6 |
|
52-Week Range
$5.01
| |
About NOVAVAX INC (NVAX)
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NOVAVAX INC (NVAX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NOVAVAX INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NOVAVAX INC's debt ratio?
NOVAVAX INC's debt ratio is 15.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 21.1%.
What are NOVAVAX INC's key financial metrics?
NOVAVAX INC has a market capitalization of $1.4B, trailing P/E ratio of 3.3, and revenue of $1.1B. The company maintains a gross margin of 63.5% and a net margin of 39.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.